Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price

By Michael Dabaie

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY) said Monday they will offer Praluent at a reduced U.S. list price.

Praluent will be available at a reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March.

With the new lower-priced Praluent, most Medicare Part D patients are expected to pay between $25 to $150 per month, depending on their insurance plan, the companies said. Praluent is a treatment for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.

The companies in March 2018 committed to lower the U.S. net price for payers in return for helping to reduce access barriers for appropriate patients, the companies said.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

February 11, 2019 07:42 ET (12:42 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.